SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ABUS reported Third Quarter 2026 results. The stock moved +2.7% on the print.
ABUSearnings

Earnings reactions, page 4

Arbutus Biopharma Corporation (ABUS) Q3 FY2026 earnings

November 10, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue was $0.3 million for the quarter ended September 30, 2026, compared to $0.5 million for the quarter ended September 30, 2025.
  • Net income for the quarter ended September 30, 2026 was $59.1 million, or $0.30 per basic and diluted common share, compared to a net loss of $7.7 million, or $0.04 per basic and diluted common share, for the quarter ended September 30, 2025.
  • Research and development expenses were $2.6 million for the quarter ended September 30, 2026, compared to $5.8 million for the same period in 2025.
  • General and administrative expenses were $8.0 million for the quarter ended September 30, 2026, compared to $3.0 million for the same period in 2025.
  • Cash, cash equivalents and investments in marketable securities were $337.5 million as of September 30, 2026, compared to $91.5 million as of December 31, 2025.

Price and volatility reaction

The stock moved +2.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +10.0 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release3.722026-11-09
Close after release3.822026-11-10
Realised move+2.7%close to close
30d ATM IV change+10.0 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-10 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →